Hui C. Liu

1.4k total citations
13 papers, 993 citations indexed

About

Hui C. Liu is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Hui C. Liu has authored 13 papers receiving a total of 993 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 9 papers in Virology and 6 papers in Emergency Medicine. Recurrent topics in Hui C. Liu's work include HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (9 papers) and HIV-related health complications and treatments (6 papers). Hui C. Liu is often cited by papers focused on HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (9 papers) and HIV-related health complications and treatments (6 papers). Hui C. Liu collaborates with scholars based in United States, United Kingdom and Thailand. Hui C. Liu's co-authors include Brian P. Kearney, Javier Szwarcberg, Calvin Cohen, Edwin DeJesus, Andrew Cheng, Anthony Mills, Joel E. Gallant, Kirsten White, Paul E. Sax and Andrew Zolopa and has published in prestigious journals such as The Lancet, Langmuir and AIDS.

In The Last Decade

Hui C. Liu

13 papers receiving 969 citations

Peers

Countries citing papers authored by Hui C. Liu

Since Specialization

Citations

This map shows the geographic impact of Hui C. Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui C. Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui C. Liu more than expected).

Fields of papers citing papers by Hui C. Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hui C. Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui C. Liu. The network helps show where Hui C. Liu may publish in the future.

Co-authorship network of co-authors of Hui C. Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Hui C. Liu. A scholar is included among the top collaborators of Hui C. Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hui C. Liu. Hui C. Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide 2016 ·EBioMedicine ·Nicholas Funderburg, Grace A. McComsey, Manjusha Kulkarni, Tammy Bannerman, (unknown), (unknown), Hui C. Liu, Yafeng Zhang, Qinghua Song, Liang Fang, Jason B. Dinoso, Andrew Cheng, Scott McCallister, Marshall W. Fordyce, Moupali Das	19
2	Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials 2016 ·Infection and Chemotherapy ·Jun Yong Choi, Somnuek Sungkanuparph, Thanomsak Anekthananon, Paul E. Sax, Edwin DeJesus, Howard Edelstein, Mark Nelson, (unknown), Hui C. Liu, Raji Swamy, (unknown), (unknown), (unknown), Christopher Ng, David Piontkowsky	1
3	Brief Report 2015 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Joel E. Gallant, Ellen Koenig, Jaime Andrade‐Villanueva, Ploenchan Chetchotisakd, Edwin DeJesus, Francisco Antunes, Keikawus Arastéh, Giuliano Rizzardini, Jan Fehr, Hui C. Liu, Michael E. Abram, Huyen Cao, Javier Szwarcberg	17
4	Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy 2015 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anthony Mills, Gordon Crofoot, Cheryl McDonald, Peter Shalit, Jason Flamm, Joseph Gathe, Anita Scribner, David Shamblaw, Michael S. Saag, Huyen Cao, Hal Martin, Moupali Das, Anne Thomas, Hui C. Liu, Mingjin Yan, Christian Callebaut, Joseph M. Custodio, Andrew Cheng, Scott McCallister	121
5	A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Andrew Zolopa, Paul E. Sax, Edwin DeJesus, Anthony Mills, Calvin Cohen, David A. Wohl, Joel E. Gallant, Hui C. Liu, Andrew Plummer, Kirsten White, Andrew Cheng, Martin S. Rhee, Javier Szwarcberg	122
6	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks 2012 ·The Lancet ·Paul E. Sax, Edwin DeJesus, Anthony Mills, Andrew Zolopa, Calvin Cohen, David A. Wohl, Joel E. Gallant, Hui C. Liu, Lijie Zhong, Kitty Yale, Kirsten White, Brian P. Kearney, Javier Szwarcberg, Erin Quirk, Andrew Cheng	335
7	Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function 2012 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Polina German, Hui C. Liu, Javier Szwarcberg, (unknown), Jessica L. Andrews, Brian P. Kearney, Anita Mathias	133
8	The efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF ('Quad') compared to efavirenz/emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects: primary results of study GS-US-236-0102 2012 ·Paul E. Sax, Edwin DeJesus, Anthony Mills, Andrew Zolopa, Calvin Cohen, (unknown), Joel E. Gallant, Hui C. Liu, Kirsten White, Erin Quirk, Brian P. Kearney	1
9	Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection 2011 ·AIDS ·Richard Elion, Calvin Cohen, Joseph Gathe, Peter Shalit, Trevor Hawkins, Hui C. Liu, Anita Mathias, Steven L. Chuck, Brian P. Kearney, David R. Warren	76
10	Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection 2011 ·AIDS ·Calvin Cohen, Richard Elion, Peter Ruane, David Shamblaw, Edwin DeJesus, Bruce Rashbaum, Steven L. Chuck, Kitty Yale, Hui C. Liu, David R. Warren, S. Ramanathan, Brian P. Kearney	93
11	Self-Assembled Biomimetic Superhydrophobic CaCO₃ Coating Inspired from Fouling Mineralization in Geothermal Water 2011 ·Langmuir ·(unknown), Li Zhu, Hui C. Liu, (unknown)	34
12	Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz 2011 ·AIDS Care ·Vanessa Cooper, Graeme Moyle, Monica Fisher, Geraldine Reilly, (unknown), Hui C. Liu, Rob Horne, (unknown)	38
13	<title>Nuclear radiation effects on GaAs/AlGaAs quantum well infrared photodetectors</title> 1996 ·Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE ·Hui C. Liu, Paul Wilson, M. Buchanan, Shyam M. Khanna	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact